Yuanqi Biomedical Technology

Yuanqi Biomedical Technology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of innovative small molecule drugs. Founded in 2021 by Dr. Yuanhua Ding, a former executive at Pfizer, the company leverages a sophisticated structure-based drug design (SBDD) platform and protein degradation technologies to target unmet needs in oncology and immunology. Its lead asset, YQ-01, is a highly selective Tyrosine kinase 2 (TYK2) inhibitor currently undergoing clinical evaluation for the treatment of autoimmune disorders such as psoriasis. Yuanqi Bio has secured significant venture capital funding to advance its pipeline of potentially best-in-class and first-in-class therapeutics.